journal
MENU ▼
Read by QxMD icon Read
search

Surgical Oncology Clinics of North America

journal
https://www.readbyqxmd.com/read/29132570/integrating-new-knowledge-and-surgical-innovation-into-the-diagnosis-and-management-of-breast-cancer
#1
EDITORIAL
Kelly K Hunt
No abstract text is available yet for this article.
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132569/innovation-in-the-diagnosis-and-management-of-breast-cancer
#2
EDITORIAL
Timothy M Pawlik
No abstract text is available yet for this article.
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132568/molecular-subtypes-and-local-regional-control-of-breast-cancer
#3
REVIEW
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss
In the era of personalized medicine, there has been significant progress regarding the molecular analysis of breast cancer subtypes. Research efforts have focused on how classification of subtypes could provide information on prognosis and influence treatment planning. Although much is known about the impact of different molecular subtypes on disease-specific survival, more recent studies have investigated the role of the different molecular subtypes on local-regional recurrence. This is an area of active study, and in recent years there has been significant progress...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132567/lobular-breast-cancer-different-disease-different-algorithms
#4
REVIEW
Anita Mamtani, Tari A King
Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, with a unique pathogenesis and distinct clinical biology. ILCs display a characteristic loss of E-cadherin, are largely estrogen receptor positive, HER2 negative, and low to intermediate grade. These features portend a favorable prognosis, but there is a tendency for late recurrences and atypical metastases. ILCs tend to be insidious and infiltrative, which can pose a challenge for diagnosis, and emerging data suggest they may have a propensity for a differing response to standard therapies...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132566/are-there-alternative-strategies-for-the-local-management-of-ductal-carcinoma-in-situ
#5
REVIEW
Kelly J Rosso, Anna Weiss, Alastair M Thompson
The management of ductal carcinoma in situ (DCIS) has traditionally followed the evidence base for invasive breast cancer using surgery, radiation therapy, and drug therapy to remove the DCIS from the breast and reduce the risk of recurrence for both DCIS and invasive breast cancer. Because of concerns regarding the overtreatment of DCIS, randomized controlled trials have been established to test the outcomes (invasive breast cancer outcomes and patient-reported outcome measures) of active surveillance compared with guideline-concordant care for low-risk (for progression) DCIS...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132565/anatomy-and-breast-cancer-staging-is-it-still-relevant
#6
REVIEW
Jennifer K Plichta, Brittany M Campbell, Elizabeth A Mittendorf, E Shelley Hwang
Breast cancer staging concisely summarizes disease status, creating a framework for assessing and relaying prognostic information. The fundamental concepts and components of breast cancer staging are reviewed. The AJCC Cancer Staging Manual, which includes traditional anatomic factors, now includes additional tumor characteristics: tumor grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and (when available) multigene panel testing from the primary tumor...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132564/tomosynthesis-in-breast-cancer-imaging-how-does-it-fit-into-preoperative-evaluation-and-surveillance
#7
REVIEW
Mohammad Eghtedari, Catherine Tsai, Julie Robles, Sarah L Blair, Haydee Ojeda-Fournier
An important limitation of conventional two-dimensional mammography is the overlap of dense breast tissue obscuring masses. Digital breast tomosynthesis (DBT) has emerged as a mammographic technology that overcomes this limitation and is considered an overall better mammogram. DBT has been shown to detect significantly more breast cancer than conventional two-dimensional mammography, and to decrease the number of callbacks for diagnostic evaluation from screening mammography. Usually the callback evaluation is deemed to be overlap of tissue requiring no further management...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132563/when-does-atypical-ductal-hyperplasia-require-surgical-excision
#8
REVIEW
Jennifer M Racz, Amy C Degnim
Atypical ductal hyperplasia (ADH) is a proliferative, nonobligate precursor breast lesion and a marker of increased risk for breast carcinoma. Surgical excision remains the standard recommendation following a core needle biopsy result consistent with ADH. Recent research suggests that women with no mass lesion or discordance, removal of greater than or equal to 90% of calcifications at the time of core needle biopsy, involvement of less than or equal to 2 terminal duct lobular units, and absence of cytologic atypia or necrosis are likely to have a less than 5% chance of a missed cancer...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132562/breast-cancer-disparities-how-can-we-leverage-genomics-to-improve-outcomes
#9
REVIEW
Melissa B Davis, Lisa A Newman
Breast cancer mortality rates are higher in African American compared with white American women. Disproportionately rising incidence rates, coupled with higher rates of biologically aggressive disease among African Americans is resulting in a widening of the mortality disparity. Higher rates of triple-negative breast cancer among African American women, as well as women from western sub-Saharan Africa, has prompted questions regarding the role of African ancestry as a marker of hereditary susceptibility for specific disease phenotypes...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132561/surgical-intervention-for-lymphedema
#10
REVIEW
Kristalyn Gallagher, Kathleen Marulanda, Stephanie Gray
Lymphedema is a chronic, progressive disease with no curative treatment. Breast cancer therapy is the most common cause of secondary lymphedema in the developed world. Treatment includes nonsurgical and surgical strategies. Conservative measures are reserved for subclinical lymphedema. Surgical options are divided into physiologic (to restore function) and reductive (to remove diseased tissue). Early stage disease is managed with physiologic procedures. Reductive treatment is reserved for moderate to severe staged disease owing to high morbidity...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132560/alternatives-to-standard-fractionation-radiation-therapy-after-lumpectomy-hypofractionated-whole-breast-irradiation-and-accelerated-partial-breast-irradiation
#11
REVIEW
Nisha Ohri, Bruce G Haffty
Adjuvant whole-breast irradiation (WBI) after lumpectomy has been an established standard of care for decades. Standard-fractionation WBI delivered over 5 to 7 weeks can achieve durable tumor control with low toxicity but can be inconvenient for patients and cost ineffective. Hypofractionated WBI can be completed in 3 to 4 weeks and, based on long-term randomized data, is the preferred standard of care in select patients. Accelerated partial-breast irradiation can be delivered using even shorter treatment regimens...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132559/oncoplastic-breast-reconstruction-should-all-patients-be-considered
#12
REVIEW
Mehran Habibi, Kristen P Broderick, Mohamad E Sebai, Lisa K Jacobs
Oncoplastic surgery of the tissue defect from partial mastectomy should be considered for all patients. It can result in in significant asymmetries from scar contraction, skin tethering, and alterations in the nipple areolar complex location. Indications, risks, and benefits are discussed. Optimal procedures are described, considering resected specimen volume, primary tumor location, tumor to breast size ratio, and the impact on the nipple areolar complex. Indications for plastic surgery consultation and joint surgery are discussed...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132558/intraoperative-margin-assessment-in-breast-cancer-management
#13
REVIEW
Chantal Reyna, Sarah M DeSnyder
The goal of breast-conserving surgery is to excise the tumor with negative margins while achieving a successful cosmetic result. Although it is not feasible to have re-excision rates of zero, several techniques have been described to reduce the need for a return to the operating room. When rates of re-excision are high, consideration should be given to using 1 or more of these techniques. It is critical that re-excision rates are tracked when new techniques are implemented to ensure progress. In addition, attention must be paid to ensuring that cosmetic outcomes remain optimal...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132557/triple-negative-breast-cancer-who-should-receive-neoadjuvant-chemotherapy
#14
REVIEW
Lubna N Chaudhary, K Hope Wilkinson, Amanda Kong
Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132556/neoadjuvant-endocrine-therapy-who-benefits-most
#15
REVIEW
Julie Grossman, Cynthia Ma, Rebecca Aft
Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor-positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor-positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132555/considerations-in-testing-for-inherited-breast-cancer-predisposition-in-the-era-of-personalized-medicine
#16
REVIEW
Benjamin Powers, Tuya Pal, Christine Laronga
Technological advances realized through next-generation sequencing technologies coupled with the loss of the ability to patent genes have led to reduction in costs for genetic testing. As a result, more people are being identified with inherited breast cancer syndromes that may affect recommendations for surveillance and risk reduction. Surgeons, at the forefront for patients newly diagnosed with breast cancer, must keep current with the changing landscape of genetics to continue to provide appropriate counsel and care...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28923234/the-evolution-of-oncology-clinical-research-lessons-learned
#17
EDITORIAL
Maureen D Moore, John M Daly
No abstract text is available yet for this article.
October 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28923233/preface
#18
EDITORIAL
Elin R Sigurdson
No abstract text is available yet for this article.
October 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28923232/foreword
#19
EDITORIAL
Nicholas J Petrelli
No abstract text is available yet for this article.
October 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28923231/future-clinical-trials-genetically-driven-trials
#20
REVIEW
Igor Astsaturov
The design of modern oncology clinical trials seeks to match patients' cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling...
October 2017: Surgical Oncology Clinics of North America
journal
journal
31108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"